- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
SGLT2 Inhibitors: 4 Questions Go Back to Basics
The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.
The sodium glucose contransporter-2 inhibitors (SGLT2is) are a relatively new class of medications, less than 10-years-old; the first approval was for canagliflozin (Invokana) in 2013. Since then, they’ve become a mainstay of treatment for patients with type 2 diabetes (T2D) including addition to professional society treatment algorithms; the SGLT2is also have demonstrated significant benefit in other health conditions in patients with and without T2D.
How much do you know about this important class of medications? Find out with these 4 questions.
images ©molekuul.be/stock.adobe.com
